Cancer Discov. 2013 Dec;3(12):OF9. doi: 10.1158/2159-8290.CD-ND2013-025. Epub 2013 Nov 7.

Targeting resistance in lung cancer.

[No authors listed]

Abstract

Two investigational drugs, AstraZeneca's AZD9291 and Clovis Oncology's CO-1686, both showed encouraging results in early trials of patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have developed resistance to targeted therapies. Pfizer's investigational agent PF-06463922, developed for patients with ALK-mutated NSCLC who have developed resistance to crizotinib, demonstrated strong activity and selectivity in preclinical research and will be studied in a phase I clinical trial launching by year-end.